Highlands Oncology Group .

Fayetteville, Arkansas 72762

7 studies enrolling now · 115 studies all time

What they study most

ALK Positive Malignancies, Adenocarcinoma, Advanced Breast Cancer, Advanced HER2+Breast Cancer, Advanced Malignant Solid Tumors, Advanced Non-Small Cell Lung Cancer, Advanced Renal Cell Carcinoma, Advanced Solid Tumor, Advanced Triple Negative Breast Cancer (TNBC) With High TAMs, Advanced or Metastatic Renal Cell Carcinoma, Advanced, Metastatic Breast Cancer, Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors

Studies at this site

• An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. — Recruiting now
• Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer — Recruiting now
• Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer — Recruiting now
• Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer — Recruiting now
• Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer — Recruiting now
• A Study of Sigvotatug Vedotin in Advanced Solid Tumors — Recruiting now
• Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET — Recruiting now
• Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] — Running, not enrolling
• Avelumab Program Rollover Study — Running, not enrolling
• Roll-over Study to Allow Continued Access to Ribociclib — Running, not enrolling
• Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation — Running, not enrolling
• Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study — Running, not enrolling
• Study of PF-07265807 in Participants With Metastatic Solid Tumors. — Stopped early
• Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. — Completed
• A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. — Stopped early
• Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2 — Completed
• TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) — Running, not enrolling
• Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM — Completed
• A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer — Stopped early
• A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer — Stopped early
• Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma — Completed
• A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer — Running, not enrolling
• A Study of PF-06873600 in People With Cancer — Stopped early
• A Study of LY3405105 in Participants With Advanced Cancer — Stopped early
• Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients — Stopped early
• Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects — Running, not enrolling
• Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma — Running, not enrolling
• Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer — Running, not enrolling
• Connect® Myeloid Disease Registry — Stopped early
• RTA 408 Capsules in Patients With Melanoma - REVEAL — Completed
• Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer — Completed
• Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. — Completed
• LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib — Completed
• Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK) — Stopped early
• UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma — Completed
• Vaccination of High Risk Breast Cancer Patients — Completed
• Vaccination of Triple Negative Breast Cancer Patients — Completed
• Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer — Completed
• Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A — Stopped early
• A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma — Completed
• Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. — Completed
• A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma — Completed
• A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy — Completed
• Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC — Completed
• Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer — Completed
• Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors — Stopped early
• Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC) — Completed
• A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer — Completed
• A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) — Completed
• A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer — Stopped early